iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to transforming the lives of people living with cancer by designing and developing next generation immunotherapies targeting two key resistance pathways to checkpoint therapy: the adenosine pathway and regulatory T cells (Tregs). The Company's lead program, EOS-850, is a best-in-class adenosine A2A receptor antagonist currently in a Phase 1/2 study. Its second program, a fully human ADCC-enabling anti-TIGIT antibody (EOS-448), entered the clinic in February 2020. iTeos Therapeutics is headquartered in Cambridge, MA with a world-class research center in Gosselies, Belgium.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/01/20 | $125,000,000 | Series B-2 |
6 Dimensions Capital Boxer Capital  Curative Ventures Fund+ HBM Partners Invus Janus Henderson Investors MPM Capital RA Capital Management RTW Investments SRIW VIVES Louvain Technology Fund | undisclosed |
